Key Points As several mechanisms lead to -cell failure in type 1 diabetes mellitus (T1DM), strategies combining different molecules could target different pathways involved in the pathogenesis of T1DM Different combination therapies have been tested in preclinical studies with encouraging results, but results from clinical trials have not matched expectations Heterogeneity in the age of patients with T1DM and the low rate of human -cell regeneration are possible explanations for the negative results of clinical trials that should be addressed in future studies Proton pump inhibitors and incretin-based agents can stimulate -cell regeneration, so future trials in patients with T1DM should investigate their potential in combination with immunomodulatory compounds The issue of patient heterogeneity can be addressed by designing trials evaluating the relative effectiveness of interventions in specific subgroups of patients Abstract Immunotherapies for type 1 diabetes mellitus (T1DM) have been the focus of intense basic and clinical research over the past few decades
At Family Health Care, the focus is on safety and evidence-based results
By year 5 the medications cost 2-3 times more than surgery and by year 10 they cost 5 times or more
Together, they work synergistically to help you feel your best
Natural product-inspired synthesis of coumarin-chalcone hybrids as potential anti-breast cancer agents
Factors like age, environmental pollution, and chronic stress can deplete your stores faster than your body can replenish them, making bioavailable supplementation a helpful tool for many.
